Imatinib has been approved by the Food and Drug Administration (FDA) for the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST) expressing KIT. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.